Cue Biopharma (CUE) EBITDA Yield: History & Chart

Cue Biopharma, Inc.(CUE)

Biotechnology · Boston, MA

$23.94-0.42 (-1.73%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.

Boston, MA

29 employees

www.cuebiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Shao-Lee Lin

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Cue Biopharma, Inc. (CUE)	$173.89M	N/A	N/A	N/A	N/A
MediWound Ltd. (MDWD)vs ›	$172.77M	N/A	16.58%	16.58%	16.58%
Precision BioSciences, Inc. (DTIL)vs ›	$172.18M	N/A	N/A	N/A	N/A
Nkarta, Inc. (NKTX)vs ›	$172.07M	N/A	N/A	N/A	N/A
Compass Therapeutics, Inc. (CMPX)vs ›	$177.78M	N/A	N/A	N/A	N/A
OptimizeRx Corp. (OPRX)vs ›	$169.41M	9.37%	9.66%	8.38%	4.23%
Journey Medical Corporation (DERM)vs ›	$179.09M	0.71%	0.65%	2.68%	2.68%
Organogenesis Holdings Inc. (ORGO)vs ›	$168.56M	0.47%	9.63%	6.71%	7.90%
Canton Strategic Holdings Inc (CNTN)vs ›	$180.85M	N/A	N/A	N/A	N/A
Coherus Oncology, Inc. (CHRS)vs ›	$165.32M	N/A	12.03%	9.31%	9.31%

NAME

MARKET CAP

EBITDA YIELD

TTM

Cue Biopharma, Inc. (CUE)

$173.89M

N/A

MediWound Ltd. (MDWD)vs ›

$172.77M

N/A

16.58%

Precision BioSciences, Inc. (DTIL)vs ›

$172.18M

N/A

Nkarta, Inc. (NKTX)vs ›

$172.07M

N/A

Compass Therapeutics, Inc. (CMPX)vs ›

$177.78M

N/A

OptimizeRx Corp. (OPRX)vs ›

$169.41M

9.37%

9.66%

8.38%

4.23%

Journey Medical Corporation (DERM)vs ›

$179.09M

0.71%

0.65%

2.68%

Organogenesis Holdings Inc. (ORGO)vs ›

$168.56M

0.47%

9.63%

6.71%

7.90%

Canton Strategic Holdings Inc (CNTN)vs ›

$180.85M

N/A

Coherus Oncology, Inc. (CHRS)vs ›

$165.32M

N/A

12.03%

9.31%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

CUE EBITDA Yield Metrics

CUE Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics